ovarian cancer
Conditions
Interventions
single drug group:Cisplatin intraperitoneal hyperthermia intraperitoneal chemotherapy
Combined drug group:cisplatin and docetaxel hyperthermic intraperitoneal chemotherapy
Sponsors
Beijing Shijitan Hospital, Capital Medical University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Aged 18-76 years; 2.Newly diagnosed patients with III and IVA stage epithelial ovarian cancer/fallopian tube cancer / primary peritoneal cancer; 3.Preoperative karnofsky performance status score (KPS)>70 scores; 4.Patients who received 3-4 courses of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 carboplatin AUC 5-6 regimen intravenous chemotherapy), the disease was completely or partially response or stabilized after chemotherapy; 5.Satisfactory cytoreductive surgery (residual tumor 3.5 x 10^9/L, platelet > 100 x 10^9/Lserum creatinine 60ml/minserum bilirubin < upper limit, alanine aminotransferase and aspartate aminotransferase < 3.5 times of upper limit, alkaline phosphatase < 6 times of upper limit.
Exclusion criteria
Exclusion criteria: 1.Preoperative major organ (heart, lung, kidney, liver) dysfunction; 2.Patients with cachexia and unstable vital signs; 3.Breast cancer in the nearly five years; 4.History of malignant tumor, abdominal and pelvic radiotherapy (except thyroid tumor); 5.Known allergic or hypersensitive reactions to cisplatin or other platinum / docetaxel; 6.Anything that would not allow the programme to proceed safely; 7.Pregnancy: pregnancy test positive for women of childbearing age; 8.Patients may be referred to non-participating hospitals during treatment; 9.Poor compliance of patients; 10.Patients with mental illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| recurrence free survival; | — |
Countries
China
Contacts
Public ContactBai Wenpei, Li Yan
Beijing Shijitan Hospital, Capital Medical University
Outcome results
None listed